Pure Bioscience Stock Today
| PURE Stock | USD 0.04 0.0001 0.25% |
PerformanceWeakest
| Odds Of DistressSmall
|
Pure Bioscience is trading at 0.0401 as of the 6th of January 2026, a 0.25 percent increase since the beginning of the trading day. The stock's lowest day price was 0.039. Pure Bioscience has about a 41 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 7th of December 2025 and ending today, the 6th of January 2026. Click here to learn more.
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California. The company has 111.36 M outstanding shares of which 222.97 K shares are at this time shorted by private and institutional investors with about 2.56 trading days to cover. More on Pure Bioscience
Moving against Pure OTC Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Pure OTC Stock Highlights
| Old Names | [PureCircle Limited, Pure Global Cannabis Inc, Purefun Group AB] |
| Business Concentration | Jakarta Stock Exchange, Consumer Staples, Household Products, Household & Personal Products, Consumer Defensive (View all Sectors) |
Pure Bioscience [PURE] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.36 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Pure Bioscience's market, we take the total number of its shares issued and multiply it by Pure Bioscience's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Pure Bioscience conducts business under Household Products sector and is part of Consumer Staples industry. The entity has 111.36 M outstanding shares of which 222.97 K shares are at this time shorted by private and institutional investors with about 2.56 trading days to cover.
Pure Bioscience currently holds about 511 K in cash with (2.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Check Pure Bioscience Probability Of Bankruptcy
Ownership AllocationPure Bioscience owns a total of 111.36 Million outstanding shares. Pure Bioscience has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Pure Ownership Details
Pure Bioscience Risk Profiles
| Mean Deviation | 3.91 | |||
| Standard Deviation | 7.22 | |||
| Variance | 52.06 | |||
| Risk Adjusted Performance | (0.07) |
Pure Stock Against Markets
Picking the right benchmark for Pure Bioscience otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Pure Bioscience otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Pure Bioscience is critical whether you are bullish or bearish towards Pure Bioscience at a given time. Please also check how Pure Bioscience's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Pure Bioscience without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Competition Analyzer Now
Competition AnalyzerAnalyze and compare many basic indicators for a group of related or unrelated entities |
| All Next | Launch Module |
Pure Bioscience Corporate Management
Elected by the shareholders, the Pure Bioscience's board of directors comprises two types of representatives: Pure Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pure. The board's role is to monitor Pure Bioscience's management team and ensure that shareholders' interests are well served. Pure Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pure Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Elliott | Principal Financial and Accounting Officer and VP of Fin. | Profile | |
| Tom CPA | Pres CEO | Profile | |
| Thomas Myers | COO Director | Profile | |
| John Kasperski | VP Sales | Profile | |
| Zhinong Yan | Exec Devel | Profile |
Other Information on Investing in Pure OTC Stock
Pure Bioscience financial ratios help investors to determine whether Pure OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pure with respect to the benefits of owning Pure Bioscience security.